{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:15:14Z","timestamp":1780395314755,"version":"3.54.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T00:00:00Z","timestamp":1627257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00270-021-02925-y","type":"journal-article","created":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T20:03:28Z","timestamp":1627329808000},"page":"1755-1762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Role of Radioembolization in the Management of Liver-Dominant Metastatic Renal Cell Carcinoma: A Single-Center, Retrospective Study"],"prefix":"10.1007","volume":"44","author":[{"given":"Andras","family":"Bibok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Mhaskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Frakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hoffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan","family":"El-Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nainesh","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Altan","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayer N.","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8898-650X","authenticated-orcid":false,"given":"Bela","family":"Kis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,26]]},"reference":[{"key":"2925_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","volume":"75","author":"U Capitanio","year":"2019","unstructured":"Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of Renal Cell Carcinoma. Eur Urol. 2019;75:74\u201384.","journal-title":"Eur Urol"},{"key":"2925_CR2","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/S0140-6736(15)00046-X","volume":"387","author":"U Capitanio","year":"2016","unstructured":"Capitanio U, Montorsi F. Renal cancer Lancet Lond Engl. 2016;387:894\u2013906.","journal-title":"Renal cancer Lancet Lond Engl"},{"key":"2925_CR3","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/annonc\/mdr362","volume":"23","author":"M Bianchi","year":"2012","unstructured":"Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh Q-D, Briganti A, et al. Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol. 2012;23:973\u201380.","journal-title":"Ann Oncol"},{"key":"2925_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3892\/mco.2014.432","volume":"3","author":"S Hamada","year":"2015","unstructured":"Hamada S, Ito K, Kuroda K, Sato A, Asakuma J, Horiguchi A, et al. Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis. Mol Clin Oncol. 2015;3:63\u20138.","journal-title":"Mol Clin Oncol"},{"key":"2925_CR5","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00345-010-0560-4","volume":"28","author":"MD Staehler","year":"2010","unstructured":"Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, Karl A, et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol. 2010;28:543\u20137.","journal-title":"World J Urol"},{"key":"2925_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jvir.2016.09.025","volume":"28","author":"B Kis","year":"2017","unstructured":"Kis B, Shah J, Choi J, El-Haddad G, Sweeney J, Biebel B, et al. Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma. J Vasc Interv Radiol. 2017;28:254\u20139.","journal-title":"J Vasc Interv Radiol"},{"key":"2925_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","volume":"14","author":"DYC Heng","year":"2013","unstructured":"Heng DYC, Xie W, Regan MM, Harshman LC, Bjarnason GA, Vaishampayan UN, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013;14:141\u20138.","journal-title":"Lancet Oncol"},{"key":"2925_CR8","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DYC Heng","year":"2009","unstructured":"Heng DYC, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:5794\u20139.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2925_CR9","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52\u201360.","journal-title":"Semin Liver Dis"},{"key":"2925_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00270-018-2133-7","volume":"42","author":"CG Radosa","year":"2019","unstructured":"Radosa CG, Radosa JC, Grosche-Schlee S, Z\u00f6phel K, Plodeck V, K\u00fchn JP, et al. Holmium-166 radioembolization in hepatocellular carcinoma: Feasibility and safety of a new treatment option in clinical practice. Cardiovasc Intervent Radiol. 2019;42:405\u201312.","journal-title":"Cardiovasc Intervent Radiol"},{"key":"2925_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatol Baltim Md. 2001;33:464\u201370.","journal-title":"Hepatol Baltim Md"},{"key":"2925_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/hep.27057","volume":"60","author":"M Vouche","year":"2014","unstructured":"Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatol Baltim Md. 2014;60:192\u2013201.","journal-title":"Hepatol Baltim Md"},{"key":"2925_CR13","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.eururo.2008.12.026","volume":"57","author":"S Naito","year":"2010","unstructured":"Naito S, Yamamoto N, Takayama T, Muramoto M, Shinohara N, Nishiyama K, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol. 2010;57:317\u201325.","journal-title":"Eur Urol"},{"key":"2925_CR14","first-page":"177","volume":"27","author":"RJ Amato","year":"2000","unstructured":"Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000;27:177\u201386.","journal-title":"Semin Oncol"},{"key":"2925_CR15","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.jvir.2019.12.794","volume":"31","author":"P Schullian","year":"2020","unstructured":"Schullian P, Putzer D, Eberle G, Laimer G, Bale R. Simultaneous Stereotactic Radiofrequency Ablation of Multiple (\u2265 4) Liver Tumors: Feasibility, Safety, and Efficacy. J Vasc Interv Radiol. 2020;31:943\u201352.","journal-title":"J Vasc Interv Radiol"},{"key":"2925_CR16","first-page":"587","volume":"17","author":"E Jonasch","year":"2019","unstructured":"Jonasch E. NCCN Guidelines Updates: Management of Metastatic Kidney Cancer. J Natl Compr Cancer Netw JNCCN. 2019;17:587\u20139.","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"2925_CR17","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378:1277\u201390.","journal-title":"N Engl J Med"},{"key":"2925_CR18","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380:1116\u201327.","journal-title":"N Engl J Med"},{"key":"2925_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816047","author":"RJ Motzer","year":"2019","unstructured":"Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1816047.","journal-title":"N Engl J Med"},{"key":"2925_CR20","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1007\/s00330-008-0887-z","volume":"18","author":"M Nabil","year":"2008","unstructured":"Nabil M, Gruber T, Yakoub D, Ackermann H, Zangos S, Vogl TJ. Repetitive transarterial chemoembolization (TACE) of liver metastases from renal cell carcinoma: local control and survival results. Eur Radiol. 2008;18:1456\u201363.","journal-title":"Eur Radiol"},{"key":"2925_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000489995","volume":"11","author":"JJ Adashek","year":"2018","unstructured":"Adashek JJ, Salgia M, Dizman N, Kessler J, Pal SK. Concomitant radioembolization and immune checkpoint inhibition in metastatic renal cell carcinoma. Case Rep Oncol. 2018;11:276\u201380.","journal-title":"Case Rep Oncol"},{"key":"2925_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jvir.2011.11.007","volume":"23","author":"MHK Abdelmaksoud","year":"2012","unstructured":"Abdelmaksoud MHK, Louie JD, Hwang GL, Kothary N, Minor DR, Sze DY. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver. J Vasc Interv Radiol. 2012;23:323-330.e1.","journal-title":"J Vasc Interv Radiol"},{"key":"2925_CR23","doi-asserted-by":"crossref","unstructured":"Riaz A, Awais R, Salem R. Side Effects of Yttrium-90 Radioembolization. Front Oncol [Internet]. 2014 [cited 2020 Nov 23];4. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4114299\/.","DOI":"10.3389\/fonc.2014.00198"},{"key":"2925_CR24","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jvir.2008.01.003","volume":"19","author":"B Atassi","year":"2008","unstructured":"Atassi B, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, et al. Biliary Sequelae following Radioembolization with Yttrium-90 Microspheres. J Vasc Interv Radiol Elsevier. 2008;19:691\u20137.","journal-title":"J Vasc Interv Radiol Elsevier"},{"key":"2925_CR25","doi-asserted-by":"crossref","unstructured":"Spina JC, Hume I, Pelaez A, Peralta O, Quadrelli M, Garcia Monaco R. Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors. Radiogr Rev Publ Radiol Soc N Am Inc. 2019;39(2): 578\u201395.","DOI":"10.1148\/rg.2019180095"},{"key":"2925_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5114\/pjp.2016.59477","volume":"67","author":"O Ferician","year":"2016","unstructured":"Ferician O, Cimpean AM, Ceausu AR, Dema A, Raica M, Cumpanas A. Heterogeneous vascular patterns in renal cell carcinomas. Pol J Pathol Off J Pol Soc Pathol. 2016;67:46\u201353.","journal-title":"Pol J Pathol Off J Pol Soc Pathol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-021-02925-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-021-02925-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-021-02925-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T20:03:27Z","timestamp":1635278607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-021-02925-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,26]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["2925"],"URL":"https:\/\/doi.org\/10.1007\/s00270-021-02925-y","relation":{},"ISSN":["0174-1551","1432-086X"],"issn-type":[{"value":"0174-1551","type":"print"},{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,26]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Formal Consent"}},{"value":"Informed consent was obtained from all individual patients included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"For this type of study, consent for publication is not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publication Consent"}}]}}